Abstract

Herein, we report the synthesis and biological characterization of the new peptide psi RGDechi as the first step toward novel targeted theranostics in melanoma. This pseudopeptide is designed from our previously reported RGDechi peptide, known to bind selectively alpha(v)beta(3) integrin, and differs for a modified amide bond at the main protease cleavage site. This chemical modification drastically reduces the enzymatic degradation in serum, compared to its parental peptide, resulting in an overall magnification of the biological activity on a highly expressing alpha(v)beta(3) human metastatic melanoma cell line. Selective inhibition of cell adhesion, wound healing, and invasion are demonstrated; near infrared fluorescent t psi RGDechi derivative is able to detect alpha(v)beta(3) integrin in human melanoma xenografts in a selective fashion. More, molecular docking studies confirm that psi RGDechi recognizes the receptor similarly to RGDechi. All these findings pave the way for the future employment of this novel peptide as promising targeting probe and therapeutic agent in melanoma disease.

Autore Pugliese

• Saviano Michele

Tutti gli autori

• Comegna D.; Zannetti A.; Del Gatto A.; de Paola I.; Russo L.; Di Gaetano S.; Liguoro A.; Capasso D.; Saviano M.; Zaccaro L.

Titolo volume/Rivista

Journal of medicinal chemistry

Anno di pubblicazione

2017

ISSN

0022-2623

ISBN

Non Disponibile

Numero di citazioni Wos

Nessuna citazione

Ultimo Aggiornamento Citazioni

Non Disponibile

Numero di citazioni Scopus

Non Disponibile

Ultimo Aggiornamento Citazioni

Non Disponibile

Settori ERC

Non Disponibile

Codici ASJC

Non Disponibile